Aon released its first workforce-focused study on GLP-1 medications, analyzing data from over 50 million commercially insured lives in the US.
The report shows that GLP-1 users experienced significantly improved health outcomes and a slower growth in healthcare costs. Specifically, after the initial rise in treatment costs, medical spend growth among GLP-1 users was seven percentage points lower in the second year compared to a matched control group. Users also had a 44 percent reduction in major cardiovascular-related hospitalizations and showed reduced incidence of several other chronic conditions.
Aon has implemented its own GLP-1 weight management program for its US employees, combining access to medication with virtual wellness support through eMed. This includes at-home blood testing, AI-driven monitoring, and 24/7 assistance. The initiative aims to boost medication adherence, support holistic health, and ultimately improve productivity while lowering long-term costs.
Aon plans to present its findings at the Milken Institute Global Conference, highlighting the economic and health value of addressing obesity with comprehensive support strategies. The company encourages other employers to adopt similar programs to help reshape workforce health and reduce chronic disease burdens.